Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer: application model for practice.

ABSTRACT:

Background

Homologous recombination deficiency (HRD) affects breast cancer patients. Treatment guided by multigene testing may be particularly beneficial in HRD patients by using platinum-based drugs and poly ADP-ribose polymerase inhibitor (PARPi). However, the optimal method for HRD testing remains undetermined by guidelines or consensus and economic disparities limit the availability of genetic testing. Prioritizing HRD testing by clinical-genomic characteristics is critical for efficient utilization of healthcare resources and improved treatment accuracy.

Methods

A total of 93 breast cancer patients who underwent HRD genetic testing were included in the study. According to the machine learning model called genomic scar (GS) HRD was defined as a genomic scar score (GSS) ≥

SUBMITTER: Du J 

PROVIDER: S-EPMC11974012 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature